Abstract
Fecal calprotectin has been evaluated on its ability to differentiate between ulcerative colitis (UC) and irritable bowel syndrome (IBS). Hence, sixty patients were stratified according to clinical and histological characteristic as UC (Group A) and IBS (Group B). The levels of calprotectin in UC patients (623.5 0 g) were significantly higher than in IBS patients (36.4 0 g), (p < 0.001). The high presence was observed in 93.3 percent of UC subjects and only 6.7 percent of IBS subjects. Thus, fecal calprotectin works well in distinguishing UC and IBS, and facilitates the non-invasive diagnosis of UC.